VRCA — Verrica Pharmaceuticals Cashflow Statement
0.000.00%
- $39.20m
- $61.95m
- $7.57m
- 20
- 22
- 38
- 14
Annual cashflow statement for Verrica Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -42.7 | -35.1 | -24.5 | -67 | -76.6 |
| Depreciation | |||||
| Non-Cash Items | 10.8 | 7.79 | 7.18 | 18 | 12.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.64 | -0.535 | -1.8 | 9.86 | 2.03 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -30.2 | -27.6 | -18.6 | -38.6 | -60.9 |
| Capital Expenditures | -1.47 | -0.883 | -0.302 | -0.362 | -0.027 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -2.11 | -0.115 | 54.3 | 0 | 0.008 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.58 | -0.998 | 54 | -0.362 | -0.019 |
| Financing Cash Flow Items | 0.319 | 0 | -0.017 | -0.176 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 35.2 | 33.6 | -16.9 | 74.2 | 37.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.45 | 5.07 | 18.5 | 35.3 | -23.2 |